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Abstract. Bevacizumab (BV) is a humanized monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial
growth factor (VEGF). The addition of BV to combination
chemotherapy has been shown to improve the outcomes in several
malignancies, including colorectal carcinoma (CRC). However,
the use of BV has been associated with adverse effects, including
hypertension, hemorrhage, proteinuria, delayed wound healing
and bowel perforation. Pneumothorax (PTX) as an adverse event
associated with BV use has rarely been reported. We herein
report the case of a 68‑year‑old female patient with a history
of metastatic CRC treated with combination chemotherapy,
including BV, who presented with complaints of shortness of
breath and was found to have a right‑sided PTX.

events, mainly cardiovascular and cerebrovascular events (5).
However, pneumothorax (PTX) has rarely been reported in
association with the use of BV (6‑12). We herein report the
case of a 68‑year‑old female patient who was undergoing
third‑line chemotherapy with folinic acid, fluorouracil (5‑FU)
and oxaliplatin (FOLFOX) plus BV when she presented with
shortness of breath (SOB) and was diagnosed with pneumohydrothorax. We consider the present case to be important, as it
sheds light on a rare adverse event associated with the use of
BV, in an era where VEGF‑inhibitors are being implemented
in the treatment of several malignancies. Clinicians should be
aware of this potential adverse event in order to possess a high
clinical index of suspicion for making this diagnosis.

Introduction

Case report

The vascular endothelial growth factor (VEGF)/VEGF‑
receptor pathway plays a key role in malignant tumor
angiogenesis (1). This has led to the development of humanized
monoclonal antibodies targeted against this pathway to inhibit
tumor angiogenesis. Bevacizumab (BV) was the first approved
anti‑VEGF antibody (2) and it has become a standard part of
several combination chemotherapy regimens used in patients
with metastatic colorectal cancer (mCRC), after having been
shown by several clinical trial to exert a statistically significant
favorable effect on overall survival (OS) and progression‑free
survival (PFS) (3). Some of the most common adverse
events associated with the use of BV include hypertension,
hemorrhage, proteinuria, delayed wound healing and bowel
perforation (4). Some have reported increased risk of arterial

A 68‑year‑old female patient presented in January 2018 to
Saint Joseph's Hospital (Chicago, USA) with complaints of
worsening SOB for 1 month, with an associated right‑sided
pleuritic chest pain and a dry cough. On physical examination,
the patient was found to be mildly tachycardic to 102 beats
per min, she was not tachypneic and her oxygen saturation was
98% breathing ambient air. Physical examination was notable
for decreased breath sounds over the right lower lung fields.
Otherwise, the physical examination was unremarkable. This
presentation was 1 week after the completion of the 4th cycle of
combination chemotherapy with FOLFOX and BV for mCRC.
The patient was initially diagnosed with stage IIIB mCRC
9 years earlier, for which she had undergone sigmoidectomy
and completed 12 cycles of adjuvant chemotherapy with
FOLFOX. Four years later, a positron emission tomography
with computed tomography (PET/CT) scan revealed disease
recurrence, with 3 metastatic lung lesions. The patient subsequently underwent Cyberknife therapy followed by 12 cycles of
leucovorin, 5‑FU and irinotecan (FOLFIRI) with cetuximab,
followed by maintenance therapy with cetuximab. Two years
later, a CT scan of the abdomen revealed evidence of a new
left adrenal mass, which was treated with radiofrequency ablation; a biopsy was consistent with metastatic adenocarcinoma.
The patient was then placed on combination chemotherapy
with FOLFIRI and BV followed by maintenance capecitabine,
which she tolerated well, and a PET/CT scan 1 year later showed
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Figure 1. Positron emission tomography‑computed tomography scan showing
increased metabolic activity within a right lower lobe lung mass.

no evidence of disease. However, 3 months later, an elevation
in her carcinoembryonic antigen (CEA) levels was observed,
and a PET/CT scan (Fig. 1) revealed disease recurrence with
lesions in the right lung base, subcarinal mediastinal lymph
node and a left adrenal mass. The patient was then started on
combination chemotherapy with FOLFIRI and the endothelial growth factor receptor inhibitor panitumumab. Disease
progression was identified on restaging CT scan, along with
an increase of the CEA levels; hence, the decision was made to
start the patient on FOLFOX and BV. The patient had a family
history of prostate cancer in her father and heart failure in her
mother. The patient was a never smoker, and she did not drink
alcohol or use illicit drugs.
The patient underwent a chest X‑ray (Fig. 2), which revealed
evidence of a moderate hydropneumothorax encompassing
40% of the right hemithorax volume. There was also a stable
opacity within the right perihilar region, which correlated with
known metastatic disease.
The patient's PTX was considered to be secondary to the
presence of an underlying pulmonary metastatic lesion in
the setting of BV use. The patient was a never smoker, with
no underlying obstructive lung disease; she had no chronic
pulmonary conditions other than her metastatic disease that
had been present for several years; she had also not had any
recent chest trauma, or undergone any recent procedures.
The patient underwent ultrasound‑guided placement of a
10 French chest tube with evacuation of 200 ml of air. The
chest tube was kept on water seal for 5 days, then clamped
the next day, and a repeat X‑ray revealed resolution of the
PTX (Fig. 3). The chest tube was removed, and the patient
was discharged.
BV was indefinitely discontinued and substituted with
cetuximab. After the 7th cycle of chemotherapy, a restaging
PET/CT scan revealed enlargement of the right basilar
lung mass with new right hilar and mediastinal lymphadenopathy, indicating progression of disease (POD). The patient
completed 12 cycles of the current chemotherapy regimen,
and POD occurred again, after which time she was started
on trifluridine and tipiracil. The patient was then admitted to
the hospital with acute encephalopathy and was found to have
sepsis secondary to pneumonia. A CT scan of the head revealed
a 0.9‑cm metastatic lesion in the left frontal lobe. Palliative
and hospice care were recommended with services initiated
during the same hospitalization. The patient succumbed to the
disease 1 week after admission.

Figure 2. Right‑sided pneumothorax with pleural effusion, encompassing
~40% of the right hemithorax (arrows indicate the visceral pleura line).

Figure 3. Repeat chest X‑ray showing resolution of previously noted pneumothorax with chest tube placement.

Discussion
BV is a recombinant humanized monoclonal antibody that
exerts antitumor effects by binding to VEGF and inhibiting
tumor angiogenesis (1). BV has been widely used in the treatment of solid tumors, including CRC, renal cell carcinoma,
ovarian carcinoma and several others (4). BV has several
side effects pertaining to its antiangiogenic effects. However,
PTX as a complication of BV use has rarely been reported.
MEDLINE was searched using two keywords, namely ‘BV’
and ‘pneumothorax’; the search yielded a total of 15 results,
7 of which were case reports relevant to the topic, and
6 of which had text available in English (Table I).
In 5 of the reviewed cases, including the present case,
pulmonary metastases were present. However, Zhang et al
reported a case of PTX following treatment of fibrosarcoma
where no lung lesions were present. Hence, PTX may occur
even in the absence of metastatic disease. Patients with mCRC
were more likely to develop PTX with BV (n=3), as compared
with fibrosarcoma (n=1), synovial sarcoma (n=1) and breast
cancer (n=1). It remains unclear whether this observation is a

Koh et al, 2013
1
54/M
NSCLC
Unknown
BV + carboplatin + paclitaxel
Unknown
Iida et al, 2016
1
57/M
CRC
Yes
BV + XELOX followed by
8 of first regimen and
					
BV + FOLFIRI
5 of second regimen
							
							
Bazan et al, 2014
1
38/M
Synovial sarcoma Yes
BV + temozolomide
3
Ueda et al, 2015
1
56/F
Breast cancer
Yes
BV + paclitaxel
NA

PTX, pneumothorax; BV, bevacizumab; CRC, colorectal carcinoma; DP, docetaxel, cisplatin; M, male; F, female; NRSTS, non‑rhabdomyosarcoma soft tissue sarcoma; NSCLC, non‑small‑cell lung
carcinoma; RCC, renal cell carcinoma; VATS, video‑assisted thoracoscopic surgery; FOLFOXIRI: Folinic acid + 5‑fluorouracil + oxaliplatin + irinotecan; XELOX, capecitabine + oxaliplatin; FOLFIRI,
folinic acid + 5‑fluorouracil + irinotecan.

(11)
(12)

(9)
(10)

Conservative management
Chest drainage with aspiration
followed by pleurodesis with
blood 4 weeks later followed by
surgery
Conservative management
Endobronchial Watanabe spigot

(6)
(7)
Small‑caliber chest tube
Small‑caliber chest tube
3
2
BV + DP
BV + FOLFOXIRI
No
Yes
Fibrosarcoma
CRC
23/M
45/M
1
1
Zhang et al, 2012
Yang et al, 2011

Cancer
type
Age
(years)/sex
Patient
no.
Case
report, year

Table I. Case reports of PTX as a complication of BV.

Disease on the		
side of the PTX
Chemotherapy

No. of preceding cycles
(days since last cycle)

Management

(Refs.)
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matter of chance, considering that mCRC is the second most
common malignancy to metastasize to the lung (13), and the
fact that mCRC is one of the most common indications for BV
treatment. PTX in association with BV was observed following
a variable number of therapy cycles.
Srinivas and Varadhachary proposed that malignancy‑associated PTX may result from tumor compression
of the bronchial wall, leading to the formation of a one‑way
valve, resulting in air trapping and eventual rupture. Another
potential cause is bronchopleural fistula formation as a result
of effective chemotherapy, and spontaneous vascular occlusion
within the tumor itself (14). Hence, it is possible that the antiangiogenic effect of BV, which leads to distortion of the tumor
vasculature, may lead to PTX in peripherally located tumors.
In addition to the suggested tumor‑related mechanisms of
PTX development, a study by Kasahara et al in animal models
found that chronic treatment with VEGF inhibitors led to the
distortion of the alveolar structure through the induction of
cell apoptosis, suggesting that this may contribute to the development of emphysema (15), which is a risk factor for PTX.
Our patient had also undergone radiosurgery with Cyberknife
4 years prior to her current presentation. PTX has been reported
with Cyberknife therapy following CT‑guided fiducial placement (16), an acute complication that was not observed in our
patient. CT scan of the chest following Cyberknife therapy did
not show evidence of lung damage that would be attributable to
that therapy. However, it is possible that our patient developed
lung parenchymal damage secondary to radiation that was
undetectable on imaging modalities and may have contributed
to the development of PTX. However, we consider the PTX that
she developed to be associated with her most recent treatment
with BV in the setting of lung metastatic disease, as the PTX
developed after the 4th dose of BV, and the fact that this patient
had also received several cycles of chemotherapy following
Cyberknife therapy (12 cycles of FOLFIRI and cetuximab,
and 24 cycles of FOLFIRI and panitumumab), which were
well‑tolerated. Our patient had received BV in the past, which
she also tolerated well; however, it is worth noting that, at the
time, the patient did not display evidence of lung metastatic
disease on imaging. Therefore, underlying lung parenchymal
disease, including lung metastatic disease, may place patients at
an increased risk of developing BV‑associated PTX.
In a recent study of breast cancer patients published by
Lodola et al, a finding suggested that the intracellular Ca 2+
toolkit, which is responsible for the pro‑angiogenic effect of
VEGF, is remodeled in cancer patients and rendered insensitive to VEGF (17). This suggests that these tumor cells are
resistant to the angiogenic effect of VEGF, and may consequently be resistant to VEGF inhibitors as anti‑angiogenic
agents. This finding suggests that VEGF inhibitors (including
BV), may not have as important a role in tumor vascularization
as previously thought, and raises the possibility that PTX, in
addition to the other adverse effects of these agents, may be
a result of an off‑target effect rather than an anti‑angiogenic
effect. Further in vitro studies that investigate this off‑target
effect are required. These studies may also uncover, as the
abovementioned study, potential novel targets, such as the
store‑operated Ca2+ entry mechanism.
It is difficult to ascertain the exact frequency of
BV‑associated PTX, given the scarcity of reported cases, and
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the inability to ascertain the number of patients receiving
BV therapy annually. However, Interiano et al conducted
a retrospective analysis of selected pediatric patients with
recurrent or refractory solid malignancies who had undergone
combination therapy with BV and sorafenib with low‑dose
cyclophosphamide therapy. The goal of the analysis was
to assess the risk of developing PTX. The study reported
an unexpectedly high incidence of PTX in 11 of the 44
subjects (25%) (18). Although that study was conducted in
pediatric patients, its results are significant and suggest that
BV‑associated PTX may be occurring at higher rates than
reported as compared to healthy individuals. In comparison,
primary spontaneous PTX (PSP) in healthy individuals is estimated to occur at a rate of 7.4‑18 cases per 100,000 amongst
males, and 6 cases per 100,000 amongst females. In addition,
PSP rarely occurs after the age of 40 years (19).
It is possible that the lack of a significant number of case
reports describing PTX in association with BV therapy is due
to the lack of widespread knowledge of this association; hence,
there may be a number of unreported such cases. Therefore, it
is important to report these cases to spread awareness amongst
clinicians to this potentially life‑threatening collateral effect
of BV. There is also the need for further studies to establish
a causal association between BV and PTX and elucidate the
mechanisms underlying this effect.
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